ITCI أخبار الفوركس
Intra-Cellular Says Phase3 Trial Study 502 Of Lumateperone In MDD Meets Primary Endpoint
Biopharmaceutical company Intra-Cellular Therapies, Inc. (ITCI) announced Tuesday positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD).
RTTNews
|
843 منذ أيام
